ANTIBE THERAPEUTICS INC - ATBPF STOCK NEWS

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) announces positive pharmacokinetic results for otenaproxesul's faster-absorbing formulation, confirming safety and informing future treatment regimens for the upcoming Phase II trial. The study delivers crucial data for the trial, on track to launch in Q1 2024, and complements strong safety data previously reported. The results confirm linear, dose-proportional pharmacokinetics and lower doses needed to achieve target plasma levels compared to the original formulation, expanding the drug's safety envelope.

Antibe Therapeutics Inc. has completed the pharmacokinetic/pharmacodynamic study of otenaproxesul's faster-absorbing formulation for acute pain. The study confirmed the drug's safety and will inform treatment regimens for the upcoming Phase II trial. All treatments were well tolerated with no adverse safety signals or elevations in liver enzymes.

Antibe Therapeutics initiates PK/PD study for otenaproxesul's faster-absorbing formulation for acute pain

Antibe Therapeutics receives Health Canada's approval to initiate PK/PD study for otenaproxesul's faster-absorbing formulation, setting the stage for Phase II trial in Q1 2024.

Antibe Therapeutics announces positive results of annual meeting of shareholders

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) announced its participation in the Precision in Clinical Trials Summit in Boston on May 1-2, 2023. Chief Medical Officer Dr. Joseph Stauffer will present Antibe’s clinical program for otenaproxesul, a drug designed to provide safer pain relief alternatives to opioids and NSAIDs, particularly addressing gastrointestinal side effects. Antibe's pipeline includes ATB-352, targeting specialized pain indications and aims to develop new therapies for inflammatory bowel disease. This summit offers a platform for clinical trial professionals to discuss innovations in the field.

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF) has announced its participation in the 2023 Bloom Burton & Co. Healthcare Investor Conference on April 25-26, 2023. The Company, focused on developing safer therapies for inflammation using its hydrogen sulfide platform, will present on April 26, 2023, at 1:30 pm ET at the Metro Toronto Convention Centre.

Chief Operating Officer Scott Curtis and Chief Medical Officer Dr. Joseph Stauffer will lead the presentation. A webcast link is available on the Company’s website and will remain accessible for 90 days. The conference aims to connect investors with developments from various companies in the Canadian healthcare sector.

Antibe's pipeline includes drugs targeting GI issues from NSAIDs and alternatives for opioids. Learn more at antibethera.com.